Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

  • End date
    Nov 1, 2026
  • participants needed
  • sponsor
    Hospital Israelita Albert Einstein
Updated on 22 January 2021


This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).

Condition Graft-Versus-Host Disease, Graft-Versus-Host Disease (GVHD), Viral infection, Viral Infections, Graft-Versus-Host Disease (GVHD), Viral Infections, Bone Marrow Transplant Complications, Engraft Failure, graft versus host disease, graft-versus-host-disease, Immunologic Suppression
Treatment cyclophosphamide, ATG
Clinical Study IdentifierNCT03818334
SponsorHospital Israelita Albert Einstein
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Men and Women of Any Age
Indication for an HSCT without matched sibling donor
Have a matched unrelated donor (HLA 10 x 10 or 9 x 10)
Hematological malignancy

Exclusion Criteria

Acute leukemias not in complete response (that is > 5% blast in the bone marrow)
Chemorefractory lymphoproliferative disease
Active uncontrolled infection
HCT-CI > 3
Severe organic disfunction (heart ejection fraction < 45%, glomerular filtration rate < 50 mL.hour, pulmonary DLCO < 50%)
Previous allogeneic bone marrow transplantation
Contraindication to cyclophosphamide or ATG
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note